These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 15614026)

  • 21. Long-term effects of irbesartan and atenolol on the renin-angiotensin-aldosterone system in human primary hypertension: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA).
    Malmqvist K; Ohman KP; Lind L; Nyström F; Kahan T
    J Cardiovasc Pharmacol; 2003 Dec; 42(6):719-26. PubMed ID: 14639093
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A microarray minisequencing system for pharmacogenetic profiling of antihypertensive drug response.
    Liljedahl U; Karlsson J; Melhus H; Kurland L; Lindersson M; Kahan T; Nyström F; Lind L; Syvänen AC
    Pharmacogenetics; 2003 Jan; 13(1):7-17. PubMed ID: 12544508
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of diastolic dysfunction in hypertensive left ventricular hypertrophy.
    Bella JN
    Am J Hypertens; 2006 Sep; 19(9):937-8. PubMed ID: 16942936
    [No Abstract]   [Full Text] [Related]  

  • 24. Comparison of irbesartan vs felodipine in the regression after 1 year of left ventricular hypertrophy in hypertensive patients (the SILVER trial). Study of Irbesartan in Left VEntricular hypertrophy Regression.
    Cohen A; Bregman B; Agabiti Rosei E; Williams B; Dubourg O; Clairefond P; Brudi P; Gosse P; Guéret P
    J Hum Hypertens; 1998 Jul; 12(7):479-83. PubMed ID: 9702935
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Irbesartan and atenolol improve diastolic function in patients with hypertensive left ventricular hypertrophy.
    Müller-Brunotte R; Edner M; Malmqvist K; Kahan T
    J Hypertens; 2005 Mar; 23(3):633-40. PubMed ID: 15716707
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiac repolarization and its relation to ventricular geometry and rate in reverse remodelling during antihypertensive therapy with irbesartan or atenolol: results from the SILVHIA study.
    Malmqvist K; Kahan T; Edner M; Bergfeldt L
    J Hum Hypertens; 2007 Dec; 21(12):956-65. PubMed ID: 17637792
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial.
    Devereux RB; Dahlöf B; Gerdts E; Boman K; Nieminen MS; Papademetriou V; Rokkedal J; Harris KE; Edelman JM; Wachtell K
    Circulation; 2004 Sep; 110(11):1456-62. PubMed ID: 15326072
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effects of antihypertensive treatment on the doppler-derived myocardial performance index in patients with hypertensive left ventricular hypertrophy: results from the Swedish irbesartan in left ventricular hypertrophy investigation versus atenolol (SILVHIA).
    Liljedahl S; Kahan T; Lind L; Arnlöv J
    Echocardiography; 2009 Aug; 26(7):753-8. PubMed ID: 19486119
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment with irbesartan or atenolol improves endothelial function in essential hypertension.
    von zur Mühlen B; Kahan T; Hägg A; Millgård J; Lind L
    J Hypertens; 2001 Oct; 19(10):1813-8. PubMed ID: 11593101
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihypertensive agents. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents.
    Gottdiener JS; Reda DJ; Massie BM; Materson BJ; Williams DW; Anderson RJ
    Circulation; 1997 Apr; 95(8):2007-14. PubMed ID: 9133508
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interactive Effect of the KCNJ11 Ile337Val Polymorphism and Cigarette Smoking on the Antihypertensive Response to Irbesartan in Chinese Hypertensive Patients.
    Jiang S; Venners SA; Hsu YH; Weinstock J; Wang B; Xing H; Wang X; Xu X
    Am J Hypertens; 2016 May; 29(5):553-9. PubMed ID: 26304961
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fibrinolytic/hemostatic variables in arterial hypertension: response to treatment with irbesartan or atenolol.
    Makris TK; Stavroulakis GA; Krespi PG; Hatzizacharias AN; Triposkiadis FK; Tsoukala CG; Votteas VV; Kyriakidis MK
    Am J Hypertens; 2000 Jul; 13(7):783-8. PubMed ID: 10933570
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension.
    Thürmann PA; Kenedi P; Schmidt A; Harder S; Rietbrock N
    Circulation; 1998 Nov; 98(19):2037-42. PubMed ID: 9808602
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Beta1-adrenergic receptor gene polymorphisms and response to beta1-adrenergic receptor blockade in patients with essential hypertension.
    Karlsson J; Lind L; Hallberg P; Michaëlsson K; Kurland L; Kahan T; Malmqvist K; Ohman KP; Nyström F; Melhus H
    Clin Cardiol; 2004 Jun; 27(6):347-50. PubMed ID: 15237695
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.
    Devereux RB; de Faire U; Fyhrquist F; Harris KE; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; Hille DA; Dahlöf B
    Curr Med Res Opin; 2007 Feb; 23(2):259-70. PubMed ID: 17288679
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comparison of the effects of mibefradil and atenolol on regression of left ventricular hypertrophy in hypertensive patients.
    Höglund C; Cifkova R; Mimran A; Tenczer J; Watt A; Wilkins MR; Lindberg E
    Cardiology; 1998 May; 89(4):263-70. PubMed ID: 9643273
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group.
    Dahlöf B; Devereux R; de Faire U; Fyhrquist F; Hedner T; Ibsen H; Julius S; Kjeldsen S; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H
    Am J Hypertens; 1997 Jul; 10(7 Pt 1):705-13. PubMed ID: 9234823
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy.
    Dahlof B; Zanchetti A; Diez J; Nicholls MG; Yu CM; Barrios V; Aurup P; Smith RD; Johansson M;
    J Hypertens; 2002 Sep; 20(9):1855-64. PubMed ID: 12195129
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of protein coding polymorphisms in the kallikrein 1 gene on baseline blood pressure and antihypertensive response to irbesartan in Chinese hypertensive patients.
    Jiang S; Hsu YH; Venners SA; Zhang Y; Xing H; Wang X; Xu X
    J Hum Hypertens; 2011 May; 25(5):327-33. PubMed ID: 20613781
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association between human atrial natriuretic peptide Val7Met polymorphism and baseline blood pressure, plasma trough irbesartan concentrations, and the antihypertensive efficacy of irbesartan in rural Chinese patients with essential hypertension.
    Zhang S; Mao G; Zhang Y; Tang G; Wen Y; Hong X; Jiang S; Yu Y; Xu X
    Clin Ther; 2005 Nov; 27(11):1774-84. PubMed ID: 16368448
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.